Experiments show promising results for a drug that could lead to a lasting treatment for millions of Americans with macular degeneration.
Researchers at the University of North Carolina School of Medicine today published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease.
“We believe we may have found an optimized treatment for macular degeneration,” said senior study author Sai Chavala, MD, director of the Laboratory for Retinal Rehabilitation and assistant professor of Ophthalmology and Cell Biology & Physiology at the UNC School of Medicine. “Our hope is that MDM2 inhibitors would reduce the treatment burden on both patients and physicians.”
The research appeared Sept. 9, 2013 in the Journal of Clinical Investigation.
As many as 11 million Americans have some form of macular degeneration, which is the most common cause of central vision loss in the western world. Those with the disease find many daily activities such as driving, reading and watching TV increasingly difficult.
Currently, the best available treatment for macular degeneration is an antibody called anti-VEGF that is injected into the eye. Patients must visit their doctor for a new injection every 4-8 weeks, adding up to significant time and cost.
“The idea is we’d like to have a long-lasting treatment so patients wouldn’t have to receive as many injections,” said Chavala. “That would reduce their overall risk of eye infections, and also potentially lower the economic burden of this condition by reducing treatment costs.” Chavala practices at the Kittner Eye Center at UNC Health Care in Chapel Hill and New Bern.
All patients with age-related macular degeneration start out with the “dry” form of the disease, which can cause blurred vision or blind spots. In about 20 percent of patients, the disease progresses to its “wet” form, in which abnormal blood vessels form in the eye and begin to leak fluid or blood, causing vision loss.
While anti-VEGF works by targeting the growth factors that lead to leaky blood vessels, MDM2 inhibitors target the abnormal blood vessels themselves causing them to regress — potentially leading to a lasting effect.
Chavala and his colleagues investigated the effects of MDM2 inhibitors in cell culture and in a mouse model of macular degeneration. They found that the drug abolishes the problematic blood vessels associated with wet macular degeneration by activating a protein known as p53. “p53 is a master regulator that determines if a cell lives or dies. By activating p53, we can initiate the cell death process in these abnormal blood vessels,” said Chavala.
The Latest on: Macular degeneration
15 year study backs higher flavonoid intake for macular degeneration
on July 20, 2018 at 9:25 am
People who regularly eat oranges are less likely to develop macular degeneration than people who do not eat oranges, according to a 15 year follow up study that links flavonoids with lower risk of the ... […]
Global Macular Degeneration Ongoing Clinical Trials - Analysis & Outlook to 2022 - ResearchAndMarkets.com
on July 20, 2018 at 8:55 am
DUBLIN--(BUSINESS WIRE)--Jul 20, 2018--The "Macular Degeneration Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering. Macular Degeneration o... […]
Scientists move one step further in developing eye drops to treat age-related macular degeneration
on July 20, 2018 at 2:17 am
Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration (AMD). AMD is the leading cause of blin... […]
An orange a day keeps the macular degeneration away, early research finds
on July 19, 2018 at 11:11 am
Apples have long been touted as the fruit 'to keep the doctor away' but now oranges may be muscling up on their status, as new research has shown regularly eating oranges may significantly help in red... […]
An orange a day keeps macular degeneration away, 15-year study shows
on July 18, 2018 at 9:14 pm
People who regularly eat oranges are less likely to develop macular degeneration than people who do not, a new study carried out in Australia has shown. Researchers at the Westmead Institute for Medic... […]
How to spot age-related macular degeneration
on July 16, 2018 at 4:00 am
‘Not being able to read is the biggest nuisance.’ Photograph: Getty Images/EyeEm Fifteen years ago, Lorna Blakeney thought she had a lump of mucus in her eye. “I was sitting reading a book after lunch ... […]
Oranges Linked to Lower Risk of Macular Degeneration
on July 15, 2018 at 5:15 am
11 million Americans have some form of macular degeneration. People who regularly eat oranges are less likely to develop one of the leading causes of blindness, according to a study. Researchers based ... […]
Oranges May Keep Macular Degeneration At Bay; Eat These Foods Too!
on July 13, 2018 at 1:20 am
According to the journal American Journal of Clinical Nutrition, an orange a day keeps macular degeneration away. Macular degeneration is a common disorder among people over 65 years of age. The resea... […]
Oranges keep macular degeneration at bay
on July 13, 2018 at 12:23 am
An orange a day can keep macular degeneration away! Researchers at the Westmead Institute for Medical Research have found that people who regularly eat oranges are less likely to develop macular degen... […]
Eating oranges may help prevent macular degeneration: study
on July 12, 2018 at 10:55 pm
People who ate at least one serving of oranges every day had more than a 60 percent reduced risk of developing late macular degeneration. Researchers at the Westmead Institute for Medical Research hav... […]
via Google News and Bing News